Brief: Kaleido Initiates Controlled Clinical Study Of Microbiome Metabolic Therapy In Outpatients With Mild-To-Moderate COVID-19

Kaleido Biosciences

23/07/2020 12:22

July 23 (Reuters) - Kaleido Biosciences Inc  KLDO.O :
    * KALEIDO BIOSCIENCES INITIATES CONTROLLED CLINICAL STUDY
WITH
MASSACHUSETTS GENERAL HOSPITAL OF MICROBIOME METABOLIC THERAPY
KB109 IN OUTPATIENTS WITH MILD-TO-MODERATE COVID-19
    * KALEIDO BIOSCIENCES INC - NON-IND CLINICAL STUDY (K032)
AIMS TO
INCLUDE ABOUT 50 COVID-19 POSITIVE OUTPATIENTS WITH
MILD-TO-MODERATE DISEASE
    * KALEIDO BIOSCIENCES - TOP-LINE DATA FROM STUDY WITH
MASSACHUSETTS GENERAL HOSPITAL (K032) EXPECTED IN Q1 OF 2021

Source text for Eikon:  ID:nGNX7ptbvJ 
Further company coverage:  KLDO.O 

 ((Reuters.Briefs@thomsonreuters.com;))